385 related articles for article (PubMed ID: 23582917)
21. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
22. Carcinoid syndroma - diagnosis and management.
Kiňová S; Koreň M
Vnitr Lek; 2021; 67(5):310-314. PubMed ID: 35459398
[TBL] [Abstract][Full Text] [Related]
23. Midgut carcinoid tumours: surgical treatment and prognosis.
Kerström G; Hellman P; Hessman O
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):717-28. PubMed ID: 16253896
[TBL] [Abstract][Full Text] [Related]
24. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging.
Gopinath G; Ahmed A; Buscombe JR; Dickson JC; Caplin ME; Hilson AJ
Nucl Med Commun; 2004 Mar; 25(3):253-7. PubMed ID: 15094443
[TBL] [Abstract][Full Text] [Related]
25. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
26. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
[TBL] [Abstract][Full Text] [Related]
27. Developments in diagnosis and treatment of metastatic midgut carcinoid tumors. A review.
Taal BG; Smits M
Minerva Gastroenterol Dietol; 2005 Dec; 51(4):335-44. PubMed ID: 16282961
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine tumours.
Barakat MT; Meeran K; Bloom SR
Endocr Relat Cancer; 2004 Mar; 11(1):1-18. PubMed ID: 15027882
[TBL] [Abstract][Full Text] [Related]
29. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
30. [All patients in Sweden with metastazing carcinoid tumors in the small intestine will be studied].
Ahrén B; Ahlman H; Cedermark B; Grimelius L; Akerström G; Oberg K
Lakartidningen; 1991 Apr; 88(16):1489-90. PubMed ID: 2023499
[No Abstract] [Full Text] [Related]
31. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.
Poncet G; Faucheron JL; Walter T
World J Gastroenterol; 2010 Apr; 16(14):1696-706. PubMed ID: 20380000
[TBL] [Abstract][Full Text] [Related]
32. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
33. [Surgical and ischemic treatment in malignant carcinoid of the small intestine].
Akerström G; Ahrén B; Cedermark B; Oberg K; Rastad J; Johansson H
Lakartidningen; 1991 May; 88(21):1983-5. PubMed ID: 2056817
[No Abstract] [Full Text] [Related]
34. [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)].
Bolanowski M; Jarzab B; Handkiewicz-Junak D; Jeziorski A; Kos-Kudła B; Zajecki W;
Endokrynol Pol; 2008; 59(1):87-96. PubMed ID: 18335403
[TBL] [Abstract][Full Text] [Related]
35. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
36. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).
Bednarczuk T; Bolanowski M; Zemczak A; Bałdys-Waligórska A; Blicharz-Dorniak J; Boratyn-Nowicka A; Borowska M; Cichocki A; Ćwikła JB; Falconi M; Foltyn W; Handkiewicz-Junak D; Hubalewska-Dydejczyk A; Jarząb B; Junik R; Kajdaniuk D; Kamiński G; Kolasińska-Ćwikła A; Kowalska A; Król R; Królicki L; Kunikowska J; Kuśnierz K; Lampe P; Lange D; Lewczuk-Myślicka A; Lewiński A; Lipiński M; Londzin-Olesik M; Marek B; Nasierowska-Guttmejer A; Nowakowska-Duława E; Pałucki J; Pilch-Kowalczyk J; Rosiek V; Ruchała M; Siemińska L; Sowa-Staszczak A; Starzyńska T; Steinhof-Radwańska K; Strzelczyk J; Sworczak K; Syrenicz A; Szawłowski A; Szczepkowski M; Wachuła E; Zajęcki W; Zgliczyński W; Kos-Kudła B
Endokrynol Pol; 2017; 68(2):223-236. PubMed ID: 28540974
[TBL] [Abstract][Full Text] [Related]
38. A stepwise approach to the management of metastatic midgut carcinoid tumor.
Bhattacharyya S; Gujral DM; Toumpanakis C; Dreyfus G; Davidson BR; Davar J; Caplin ME
Nat Rev Clin Oncol; 2009 Jul; 6(7):429-33. PubMed ID: 19561636
[TBL] [Abstract][Full Text] [Related]
39. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
Wang YC; Zuraek MB; Kosaka Y; Ota Y; German MS; Deneris ES; Bergsland EK; Donner DB; Warren RS; Nakakura EK
Endocr Relat Cancer; 2010 Mar; 17(1):283-91. PubMed ID: 20048018
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
